Home LiteratureArticle Details
PMID: 19429480 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment.

Seminars in cancer biology ·Vol. 19 ·No. 3 ·2009-06-00 ·Pages 165-71

Dworkin AM, Huang TH, Toland AE

Abstract

Epigenetic alterations of the genome such as DNA promoter methylation and chromatin remodeling play an important role in tumorigenesis. Recent findings indicate epigenetic modifications as key factors in breast carcinogenesis. These modifications are quite appealing as targets for preventative care and therapeutics because of their potential for reversal. Future medical care for breast cancer patients will likely depend upon a better understanding of the roles epigenetic modifications play in carcinogenesis. Here, we discuss the importance of epigenetics in breast cancer detection, prognosis, and therapy with an emphasis on mechanisms and epigenetic contributions to field cancerization effects.

MeSH Terms
Animals Antineoplastic Agents/therapeutic use BRCA1 Protein/genetics,metabolism Breast Neoplasms/diagnosis,drug therapy,genetics DNA Methylation Epigenesis, Genetic Gene Expression Regulation, Neoplastic Gene Silencing/physiology Humans Prognosis Tumor Suppressor Proteins/genetics,metabolism
Chemicals
Antineoplastic Agents BRCA1 Protein BRCA1 protein, human RASSF1 protein, human Tumor Suppressor Proteins
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Dworkin Amy M
Integrated Biomedical Science Graduate Program, The Ohio State University, Columbus, OH 43210, USA.
Huang Tim H-M
Toland Amanda Ewart
References (56)
56 references, click to expand
  1. Wwox and Ap2gamma expression levels predict tamoxifen response.
    Clin Cancer Res. 2007 Oct 15;13(20):6115-21 PMID: 17947476
  2. Epigenetic gene silencing in cancer: the DNA hypermethylome.
    Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R50-9 PMID: 17613547
  3. DNA methylation in breast and colorectal cancers.
    Mod Pathol. 2007 Jul;20(7):711-21 PMID: 17464311
  4. DNA methylation profiles of female steroid hormone-driven human malignancies.
    Curr Top Microbiol Immunol. 2006;310:141-78 PMID: 16909910
  5. The functional significance of nuclear receptor acetylation.
    Steroids. 2007 Feb;72(2):221-30 PMID: 17291555
  6. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer.
    Breast Cancer Res Treat. 2009 May;115(2):397-404 PMID: 18521744
  7. DNA methylation in serum of breast cancer patients: an independent prognostic marker.
    Cancer Res. 2003 Nov 15;63(22):7641-5 PMID: 14633683
  8. Dual targeting of epigenetic therapy in cancer.
    Biochim Biophys Acta. 2007 Jan;1775(1):76-91 PMID: 16930846
  9. Methylation of the tumor suppressor gene RASSF1A in human tumors.
    Biochemistry (Mosc). 2005 May;70(5):576-83 PMID: 15948711
  10. Epigenetic information and estrogen receptor alpha expression in breast cancer.
    Oncologist. 2006 Jan;11(1):1-8 PMID: 16401708
  11. Epigenetic biomarkers and breast cancer: cause for optimism.
    Clin Cancer Res. 2006 Nov 15;12(22):6591-3 PMID: 17121875
  12. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer.
    Int J Cancer. 2002 May 10;99(2):305-9 PMID: 11979449
  13. Triple negative tumours: a critical review.
    Histopathology. 2008 Jan;52(1):108-18 PMID: 18171422
  14. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
    Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 PMID: 8790415
  15. Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families.
    Mod Pathol. 2007 Dec;20(12):1298-306 PMID: 17885670
  16. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy.
    Oncologist. 2005 Jun-Jul;10(6):370-81 PMID: 15967831
  17. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
    Cancer Res. 2007 Jun 1;67(11):5337-44 PMID: 17545614
  18. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis.
    Hum Mol Genet. 2001 Dec 15;10(26):3001-7 PMID: 11751682
  19. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
    Cancer Res. 2006 Feb 15;66(4):2019-27 PMID: 16489001
  20. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
    Cancer. 2004 Apr 15;100(8):1605-14 PMID: 15073846
  21. Heterogenic loss of BRCA in breast cancer: the "two-hit" hypothesis takes a hit.
    Ann Surg Oncol. 2007 Sep;14(9):2428-9 PMID: 17406948
  22. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
    Cancer Res. 2006 Dec 15;66(24):11954-66 PMID: 17178894
  23. The role of DNA methylation in cancer development.
    Folia Histochem Cytobiol. 2006;44(3):143-54 PMID: 16977793
  24. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid.
    Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3306-10 PMID: 16740751
  25. Silencing estrogen receptor alpha in breast cancer cells.
    Cancer Biol Ther. 2006 Jul;5(7):848-9 PMID: 16921265
  26. DNA methylation: an alternative pathway to cancer.
    Ann Surg. 2001 Jul;234(1):10-20 PMID: 11420478
  27. Familial invasive breast cancers: worse outcome related to BRCA1 mutations.
    J Clin Oncol. 2000 Dec 15;18(24):4053-9 PMID: 11118466
  28. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer.
    Cancer Res. 2004 Nov 15;64(22):8184-92 PMID: 15548683
  29. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays.
    Cancer Res. 2001 Dec 1;61(23):8375-80 PMID: 11731411
  30. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
    Breast Cancer Res. 2007;9(4):R57 PMID: 17764565
  31. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
    BMC Cancer. 2008 Jan 22;8:17 PMID: 18208621
  32. Epigenetic field for cancerization.
    J Biochem Mol Biol. 2007 Mar 31;40(2):142-50 PMID: 17394762
  33. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue.
    Clin Cancer Res. 2006 Nov 15;12(22):6626-36 PMID: 17121881
  34. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
    Breast Cancer Res. 2006;8(4):R38 PMID: 16846527
  35. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
    Life Sci. 2007 Jul 4;81(4):280-7 PMID: 17599361
  36. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin.
    Cancer. 1953 Sep;6(5):963-8 PMID: 13094644
  37. Promoter-associated RNA is required for RNA-directed transcriptional gene silencing in human cells.
    Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12422-7 PMID: 17640892
  38. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk.
    Clin Cancer Res. 2005 Jan 1;11(1):166-72 PMID: 15671542
  39. DNA methylation and breast carcinogenesis.
    Oncogene. 2002 Aug 12;21(35):5462-82 PMID: 12154408
  40. X inactive-specific transcript RNA coating and genetic instability of the X chromosome in BRCA1 breast tumors.
    Cancer Res. 2007 Jun 1;67(11):5134-40 PMID: 17545591
  41. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells.
    Biochem Pharmacol. 2004 Sep 15;68(6):1239-46 PMID: 15313422
  42. Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.
    Hum Mutat. 2007 May;28(5):477-85 PMID: 17279547
  43. A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology.
    BMC Genomics. 2008 Sep 16;9 Suppl 2:S23 PMID: 18831789
  44. Multiple binding of methyl-CpG and polycomb proteins in long-term gene silencing events.
    J Cell Physiol. 2007 Mar;210(3):711-9 PMID: 17133344
  45. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk.
    Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):989-95 PMID: 16467114
  46. New anti-cancer strategies: epigenetic therapies and biomarkers.
    Front Biosci. 2005 May 01;10:1897-931 PMID: 15769674
  47. Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors.
    Epigenetics. 2008 May-Jun;3(3):157-63 PMID: 18567944
  48. Quantitative assessment of DNA methylation: Potential applications for disease diagnosis, classification, and prognosis in clinical settings.
    J Mol Med (Berl). 2006 May;84(5):365-77 PMID: 16416310
  49. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients.
    Cancer Res. 2005 Feb 15;65(4):1141-5 PMID: 15734995
  50. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity.
    J Biol Chem. 2001 May 25;276(21):18375-83 PMID: 11279135
  51. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
    Breast Cancer Res. 2004;6(1):R8-R17 PMID: 14680495
  52. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene.
    J Mol Med (Berl). 2005 Feb;83(2):132-9 PMID: 15536519
  53. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
    Mol Endocrinol. 2005 Jul;19(7):1740-51 PMID: 15746193
  54. Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells.
    Cancer Res. 2008 Dec 15;68(24):10257-66 PMID: 19074894
  55. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.
    J Clin Oncol. 2000 Dec 15;18(24):4045-52 PMID: 11118465
  56. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.
    Cancer Res. 2003 Apr 15;63(8):1727-30 PMID: 12702551
Article Info
Journal
Seminars in cancer biology
Abbr.
Semin Cancer Biol
ISSN
1096-3650
DOI
10.1016/j.semcancer.2009.02.007
Published
2009-06-00
Epub
2009-00-20
Pages
165-71
Language
English
Region
England
NLM ID
9010218
PMCID
PMC2734184
Subset
IM
Grants
NCI NIH HHS · R01 CA069065 · United States
NIEHS NIH HHS · U01 ES015986-03 · United States
NCI NIH HHS · U54 CA113001-05 · United States
NCI NIH HHS · U54 CA113001 · United States
NCI NIH HHS · R01 CA069065-12 · United States
NIEHS NIH HHS · U01 ES015986 · United States
NIEHS NIH HHS · R01 ES017594 · United States
NIEHS NIH HHS · R01 ES017594-01 · United States
External Links
PubMed source DOI: 10.1016/j.semcancer.2009.02.007 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2